OUR GOAL: A WORLD WITHOUT 1

 

WE RESEARCH. WE DEVELOP. WE FIGHT.

FOR A WORLD WITHOUT TYPE 1 DIABETES.

© Helmholtz Zentrum München

 

A world without type 1 diabetes: vision or soon a reality?

Type 1 diabetes is usually only diagnosed once the affected child’s symptoms have become severe. Thanks to research carried out around the world, this need no longer be the case.

 

 


 

Fr1daplus and Fr1dolin: early detection of type 1 diabetes

© Helmholtz Zentrum München / Achim Lippoth

With the Fr1daplus study in Bavaria, children aged two to ten are tested free of charge for an early stage of type 1 diabetes. In Lower Saxony, children who take part in the Fr1dolin study up to their seventh birthday can be assessed – also free of charge – for the presence of an early stage of type 1 diabetes. This means that children who are developing type 1 diabetes can be identified early and treated in good time, thus avoiding dangerous metabolic problems.

 

 


 

Freder1k: early detection of the risk of developing type 1 diabetes

© Helmholtz Zentrum München

But GPPAD goes one step further. Recent research shows that, in children who have an increased risk of developing type 1 diabetes, the mistaken reaction of the immune system that leads to the development of type 1 diabetes often begins when the children are infants or toddlers. This is why the researchers and doctors working together through GPPAD want to prevent the development of this immune response as early as possible. To achieve this, each child’s risk of type 1 diabetes must first be determined. A new test looks at particular genes linked to type 1 diabetes. In Germany, parents in Bavaria, Lower Saxony, Saxony, and Thuringia can have their infants up to the age of four months tested for this increased risk free of charge, as part of the Freder1k study. Babies who have a parent or sibling with type 1 diabetes can participate in the Freder1k study throughout Germany, no matter where they live. These studies are being run across Europe under different names and, as part of GPPAD, identify if there is an increased genetic risk of type 1 diabetes in infants up to four months old.

 

 


 

POInT: Preventive treatment

© NiDerLander / Adobe Stock

If the child has an increased risk for type 1 diabetes, we invite them to take part in the POInT (Primary Oral Insulin Trial) prevention study. The aim of this study is to determine whether daily administration of insulin powder with food can prevent the disease from developing, in comparison with a placebo. The results of a pilot study on this were promising. There have been no side effects to date.

If this treatment with insulin powder is effective in preventing the development of type 1 diabetes, this would be a significant milestone. Type 1 diabetes could go from being an unavoidable fate to a disease that can be preventively treated.

 

 

We are working to achieve a world without type 1 diabetes.